Meritage Group’s Moderna MRNA Stock Holding History

Meritage Group’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-2,514	Closed	-$639K	–	34
2021 Q4	$639K	Buy	+2,514	New	+$735K	0.01%	19

Other funds holding MRNA

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Meritage Group's MRNA Position: Q1 2022 in Review

Meritage Group sold out of Moderna (MRNA) in Q1 2022, closing a stake of 2,514 shares — an estimated $639K sold.

Meritage Group first reported a position in MRNA in Q4 2021 and held it in 1 quarter. The position peaked at $639K in Q4 2021. 1,006 funds tracked by Wall St. Rank hold MRNA as of Q1 2022.

Meritage Group reported no remaining Moderna position as of Q1 2022 after selling out during the quarter.
Meritage Group sold 2,514 Moderna shares in Q1 2022, an estimated $639K.
Meritage Group first reported a position in Moderna in Q4 2021 and held it in 1 quarter.
Meritage Group's Moderna position peaked at $639K in Q4 2021.
1,006 funds tracked by Wall St. Rank held Moderna as of Q1 2022.

Based on Meritage Group's 13F filing for Q1 2022, filed 13 May 2022.